Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
a study on Scleroderma, Diffuse Scleroderma, Systemic Scleroderma, Limited Sclerosis, Progressive Systemic Skin Diseases Connective Tissue Diseases Pathologic Processes Autoimmune Disease High Blood Pressure
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
- Principal Investigator
- Suzanne Kafaja (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UC Health
- Suzanne Kafaja (ucla)
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cumberland Pharmaceuticals
- ID
- NCT02682511
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated